67 related articles for article (PubMed ID: 9296954)
1. [Molecular modelling and drug design: neurokinin receptor antagonism].
Boudon A; Jacoby E; Michel A
J Pharm Belg; 1997; 52(2):103. PubMed ID: 9296954
[No Abstract] [Full Text] [Related]
2. Receptors and antagonists for substance P and related peptides.
Regoli D; Boudon A; Fauchére JL
Pharmacol Rev; 1994 Dec; 46(4):551-99. PubMed ID: 7534932
[No Abstract] [Full Text] [Related]
3. Antagonists at the neurokinin receptors--recent patent literature.
Giardina GA; Gagliardi S; Martinelli M
IDrugs; 2003 Aug; 6(8):758-72. PubMed ID: 12917772
[TBL] [Abstract][Full Text] [Related]
4. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
[TBL] [Abstract][Full Text] [Related]
5. Estimation of blood levels of endothelin and neurokinin receptor antagonists at the rat portal and jugular veins after oral administration as a tool in peptide drug design.
Paladino J; Kucharczyk N; Morris AD; Thibault-Naze M; Mahieu JP; Serkiz B; Volland JP; Autissier C; Fauchere JL
Drug Des Discov; 1994 Nov; 12(2):121-8. PubMed ID: 9116167
[TBL] [Abstract][Full Text] [Related]
6. Tachykinin receptor antagonists in clinical trials.
Quartara L; Altamura M; Evangelista S; Maggi CA
Expert Opin Investig Drugs; 2009 Dec; 18(12):1843-64. PubMed ID: 19938899
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
8. Generation of a new class of hNK(2) receptor ligands using the 'fragment approach'.
D'Andrea P; Porcelloni M; Madami A; Patacchini R; Altamura M; Fattori D
Bioorg Med Chem Lett; 2005 Feb; 15(3):585-8. PubMed ID: 15664817
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in neurokinin receptor antagonists.
Shenvi AB
Curr Top Med Chem; 2003; 3(12):NA. PubMed ID: 12921087
[No Abstract] [Full Text] [Related]
10. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in neurokinin receptor antagonists.
Gao Z; Peet NP
Curr Med Chem; 1999 May; 6(5):375-88. PubMed ID: 10101218
[TBL] [Abstract][Full Text] [Related]
12. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3.
Leffler A; Ahlstedt I; Engberg S; Svensson A; Billger M; Oberg L; Bjursell MK; Lindström E; von Mentzer B
Biochem Pharmacol; 2009 May; 77(9):1522-30. PubMed ID: 19426690
[TBL] [Abstract][Full Text] [Related]
13. Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists.
Ratni H; Ballard TM; Bissantz C; Hoffmann T; Jablonski P; Knoflach F; Knust H; Malherbe P; Nettekoven M; Patiny-Adam A; Riemer C; Schmitt M; Spooren W
Bioorg Med Chem Lett; 2010 Nov; 20(22):6735-8. PubMed ID: 20850972
[TBL] [Abstract][Full Text] [Related]
14. Neurokinin receptor modulation of respiratory activity in the rabbit.
Bongianni F; Mutolo D; Cinelli E; Pantaleo T
Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia.
Catalani MP; Alvaro G; Bernasconi G; Bettini E; Bromidge SM; Heer J; Tedesco G; Tommasi S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6899-904. PubMed ID: 21974957
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
17. Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
Bissantz C; Bohnert C; Hoffmann T; Marcuz A; Schnider P; Malherbe P
J Med Chem; 2012 Jun; 55(11):5061-76. PubMed ID: 22574973
[TBL] [Abstract][Full Text] [Related]
18. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
[TBL] [Abstract][Full Text] [Related]
19. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
20. High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a common structural template.
Harrison T; Korsgaard MP; Swain CJ; Cascieri MA; Sadowski S; Seabrook GR
Bioorg Med Chem Lett; 1998 Jun; 8(11):1343-8. PubMed ID: 9871763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
